Identification of novel therapeutic targets for diabetic neuropathy through integrated proteomics and transcriptomics approaches
Authors:
- Xue-Feng DingXDXue-Feng Ding
- Xin DangXDXin Dang
- Shan LinSLShan Lin
Open Access
- 15 December 2025
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 16 (12)
Abstract
BACKGROUND Diabetic neuropathy (DN) is a progressive disorder with limited effective treatment options. AIM To identify potential therapeutic targets for DN by integrating plasma proteomic and transcriptomic data. METHODS A comprehensive analytical framework was developed to identify multi-omics biomarkers of DN. Protein-protein interaction network and Gene Ontology analyses were performed to explore the biological functions of biomarkers. Tier 1 target proteins were further analyzed. Candidate drug prediction and molecular docking studies were conducted to identify potential treatments while assessing the side effects of key target proteins. The mediation of immune cells in the association between proteins and DN was examined through two-step network Mendelian randomization (MR) analysis. RESULTS Nine DN-associated proteins were identified by analyzing protein quantitative trait loci from extensive genome-wide association study data. BTN3A1 and MICB were confirmed using MR, summary data-based MR, and colocalization analyses. Of the nine, HSPA1B, PSMB9, BTN3A1, SCGN, NOTUM, and MICB showed negative associations with DN, whereas WARS, BRD2, and CSNK2B were positive. Gene Ontology analysis indicated enrichment in inflammatory response and neuronal injury pathways. BTN3A1 and MICB were identified as Tier 1 targets. Drug prediction and molecular docking analyses indicated cyclosporin A as a potential therapeutic candidate. Two-step network MR analysis showed that MICB mediated DN through human leukocyte antigen-DR++ monocytes. These integrated findings point to an immune-mediated mechanism with translational potential and nominate BTN3A1 and MICB for focused functional validation. CONCLUSION Our integrated multi-omics approach identified two promising therapeutic targets for DN, laying the groundwork for new treatment strategies and enhancing our understanding of MICB’s role in DN.Keywords
This publication has 88 references indexed in Scilit:
- Synergistic effects of BTN3A1, SHP2, CD274, and STAT3 gene polymorphisms on the risk of systemic lupus erythematosus: a multifactorial dimensional reduction analysisClinical Rheumatology, 2023
- Ablation of Argonaute 2 in Schwann cells accelerates the progression of diabetic peripheral neuropathyGlia, 2023
- Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathyDiabetologia, 2021
- Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathyJournal of Neurology, 2020
- Erratum to: Interpreting findings from Mendelian randomization using the MR-Egger methodEuropean Journal of Epidemiology, 2017
- Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized DataGenetic Epidemiology, 2013
- Painless diabetic motor neuropathy: A variant of diabetic lumbosacral radiculoplexus Neuropathy?Annals of Neurology, 2010
- Normal renal function 8 to 13 years after Cyclosporin A therapy in 285 diabetic patientsDiabetes/Metabolism Research and Reviews, 2002
- Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectivesDiabetes/Metabolism Research and Reviews, 2002
- Ganglioside therapy in diabetic neuropathyMuscle & Nerve, 1986